I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Dung Thi Le, M.D.
Associate Professor of Oncology
Languages: English, Vietnamese
Expertise: Anal Cancer, Bile Duct Cancer, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Colon Cancer, Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Small Intestine Cancer, Stomach Cancer ...read more
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
APPOINTMENT PHONE: 410-955-8893
401 N. Broadway Baltimore, MD 21231
Phone: 443-287-0002 | Fax: 410-614-8216
Dung Le, M.D. is an associate professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer.
These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics.
- Associate Professor of Oncology
- MD, Johns Hopkins University School of Medicine (2001)
- Johns Hopkins University School of Medicine / Medicine (2004)
- Johns Hopkins University School of Medicine / Oncology (2007)
Research & Publications
Selected PublicationsView all on Pubmed
Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM. CD8(+) Foxp3(+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Internat J Cancer. Journal international du cancer. 2011;129(3):636-647. PMCID: PMC3064958. Role: Designed and performed the experiments. Conducted data analysis. Primary author on manuscript.
Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Jr., Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858-868. PMCID: PMC3289408. Role: Lead investigator on multi-institutional study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received an ASCO Career Development Award to conduct this study.
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunotherapy. 2013;36(7):382-389. PMCID: PMC3779664. Role: Principal investigator study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Wrote R21 that funded this study (R21CA126058-01A2).
Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Jan 12. PMCID: PMC4397277; Role: Lead investigator on multi-institutional study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received a K23, Career Development Award to conduct this study. 1K23CA163672
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Le JJ, Duffy SM, Goldberg RM, de la Chappelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch repair deficiency. NEJM. 2015. PMCID: PMC4481136; Role: Lead investigator on multi-institutional study. Designed and conducted study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received a GI SPORE grant to conduct microsatellite instability testing (MSI) for prescreening component of study (P50 CA62924).